Joan Bargay

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

María‐Victoria Mateos, Miguel‐Teodoro Hernández, Pilar Giraldo et al. · New England Journal of Medicine · 2013 · 569 citations · Full text

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations

Hematological Malignancy, Elderly Patients, Medicine +7

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

María‐Victoria Mateos, JoséM. Hernández, M.B. Gómez Hernández et al. · Blood · 2006 · 388 citations · Full text

Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy

Marta Pratcorona, Salut Brunet, Josep Nomdedéu et al. · Blood · 2013 · 279 citations

Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

Bruno Paiva, Noemí Puig, María‐Teresa Cedena et al. · Journal of Clinical Oncology · 2019 · 261 citations · Full text